Structural Basis for Inhibition of Human Primase by Arabinofuranosyl Nucleoside Analogues Fludarabine and Vidarabine

Sandro Holzer, Neil J. Rzechorzek, Isobel R. Short, Michael Jenkyn-Bedford, Luca Pellegrini, and Mairi L. Kilkenny

Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, U.K.

Supporting Information

ABSTRACT: Nucleoside analogues are widely used in clinical practice as chemotherapy drugs. Arabinose nucleoside derivatives such as fludarabine are effective in the treatment of patients with acute and chronic leukemias and non-Hodgkin’s lymphomas. Although nucleoside analogues are generally known to function by inhibiting DNA synthesis in rapidly proliferating cells, the identity of their in vivo targets and mechanism of action are often not known in molecular detail. Here we provide a structural basis for arabinose nucleotide-mediated inhibition of human primase, the DNA-dependent RNA polymerase responsible for initiation of DNA synthesis in DNA replication. Our data suggest ways in which the chemical structure of fludarabine could be modified to improve its specificity and affinity toward primase, possibly leading to less toxic and more effective therapeutic agents.

Prior to cell division, cells must accurately duplicate their genetic material to ensure that both daughter cells contain a full complement of genes. The process of DNA replication is carried out by a large and dynamic macromolecular assembly known as the replisome, which coordinates unwinding of the DNA duplex with DNA synthesis of both leading and lagging strands. Because replicative DNA polymerases cannot initiate DNA duplex with DNA synthesis of both leading and lagging strands, the identity of their in vivo targets and mechanism of action are often not known in molecular detail. Here we provide a structural basis for arabinose nucleotide-mediated inhibition of human primase, the DNA-dependent RNA polymerase responsible for initiation of DNA synthesis in DNA replication. Our data suggest ways in which the chemical structure of fludarabine could be modified to improve its specificity and affinity toward primase, possibly leading to less toxic and more effective therapeutic agents.

These compounds include fludarabine (2F-araAMP), vidarabine (araA), cytarabine (araC), cladribine (2Cl-da), gemcitabine (2’2’-dif-ddC), and clofarabine (2Cl-2’F-aradA). Upon cellular uptake, these analogues are biologically activated by 5’ triphosphorylation. They subsequently elicit their effects by directly inhibiting intracellular enzymes and/or by retarding or terminating nucleic acid synthesis as they are incorporated into nascent DNA and RNA strands.

Vidarabine triphosphate (vidarabine-TP) and fludarabine triphosphate (fludarabine-TP) are both ATP analogues in which the 2’-hydroxyl is in the arabino (ara) rather than the ribo configuration (Figure 1A). Vidarabine, while no longer used as a cancer treatment due to its rapid deamination in vivo, is nonetheless effective as an antiviral agent against herpes simplex virus and varicella zoster virus infections. Fludarabine, which is more resistant to deamination, is widely used as a chemotherapeutic agent to treat B-cell chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and some types of non-Hodgkin’s lymphoma. However, treatment is often associated with thrombocytopenia, anemia, neutropenia, and profound lymphopenia, thereby increasing the risk of opportunistic infections. In fact, one of the major problems with the therapeutic use of current nucleoside analogues is dose-limiting toxicity due to their nonselective nature, with...
potential targets including DNA and RNA polymerases, ribonucleotide reductase, and DNA ligase.18–24

Vidarabine-TP and fludarabine-TP are potent inhibitors of DNA replication in vivo25 and have been shown to inhibit both replicative DNA polymerases and primase in vitro.26–28

Primase incorporates ara nucleotides into primers more efficiently than normal ribonucleotides,29–31 and it has been suggested that primase inhibition may be one of the primary mechanisms for fludarabine cytotoxicity in tumor cells.32 However, deciphering which of the many nucleotide-binding enzymes are the primary targets of the ara nucleotides in vivo has proved difficult, with the result that their mechanism of cytotoxicity is still unclear.

A drug that selectively inhibits primase without significant off-target effects could be of significant therapeutic value and may be less toxic to nondividing cells.34 Importantly, recent structural information has made the design of high affinity primase inhibitors a more realistic prospect.35–36 Here we test the effect of a range of chemotherapeutic nucleoside analogues on primase activity. We also present the crystal structures of human Pri1 bound to vidarabine-TP and fludarabine-TP, thereby elucidating the mode of binding of arabinofuranosyl nucleotides to the catalytic subunit of primase and explaining the reported preference of primase for these nucleotides. We propose that these ara nucleotides represent an interesting starting point for the structure-based drug design of specific primase inhibitors.

### RESULTS AND DISCUSSION

**Inhibition of RNA Primer Synthesis by Vidarabine-TP and Fludarabine-TP.** To confirm that ara nucleotides are effective inhibitors of human primase, we analyzed their effect on RNA primer synthesis. A fluorescence-based RNA primer synthesis assay37 revealed strong inhibition of primase activity by both vidarabine-TP and fludarabine-TP (Figure 1B). While similar levels of inhibition were observed for both compounds, no inhibition was observed in the presence of 2F-ATP, confirming that it is the arabinofuranosyl moiety that is important for mediating the inhibitory effect of these nucleotide analogues. Inhibition occurred irrespective of whether the divalent metal was Mn$^{2+}$ (Figure 1B) or Mg$^{2+}$ (Supplementary Figure 1A). While both divalent metals support robust primer synthesis in vitro, Mn$^{2+}$ has been reported not only to enhance the binding of nucleotides to human primase but also to reduce the fidelity of various polymerases including primase.

These results were confirmed using denaturing gel electrophoresis to analyze the priming reaction products synthesized in the presence of increasing concentrations of fludarabine-TP (Figure 2A). We observed strong dose-dependent inhibition of RNA primer synthesis, with near complete inhibition evident at 200 μM fludarabine-TP and 500 μM ATP. In the presence of an existing RNA primer annealed to a single-stranded DNA template, providing primase with fludarabine-TP as the only available nucleotide limited primer extension to one or two nucleotides (Figure 2B). Primase added the first fludarabine moiety quickly (lane 4, first addition complete by 2 min) and the second much more slowly (lane 7, second addition complete by 30 min). An RNA primer with fludarabine incorporated at its 3’-end could not be further extended with ATP, suggesting that incorporation and capping of the growing ribonucleotide chain is a likely mechanism of action (Figure 2C). This is in agreement with previous primase studies which also describe chain termination by ara nucleotides.22,29,40

We then used a fluorescence polarization (FP) competition binding assay to compare the binding affinities of the various nucleotide analogues. In this experiment, the binding of 6FAM-labeled ATP to Pri1 was challenged by titrating in the presence of increasing concentrations of fludarabine-TP (Figure 2A). The lower $K_{1/2}$ values obtained for ara nucleotides (Table 2) compared to those for the ribo/deoxyribonucleotides ($K_{1/2}$A$^T$P = 7.5 μM, $K_{1/2}$2F-ATP = 7.2 μM, $K_{1/2}$dATP = 3.3 μM) indicate that the ara...
nucleotides indeed bind with higher affinity (Figure 3A). Using thermal denaturation, we observed that all nucleotides stabilized primase relative to the unliganded enzyme (Figure 3B). While both ara nucleotides stabilized primase to a greater extent relative to ATP, fludarabine-TP imparted far greater thermal stability than vidarabine-TP \( \left( T_{m}^{\text{ATP}} = 53.8 \pm 0.3 ^\circ\text{C}, \; T_{m}^{\text{ara}} = 54.4 \pm 0.2 ^\circ\text{C}, \; T_{m}^{\text{fludarabine-TP}} = 58.0 \pm 0.2 ^\circ\text{C} \right) \).

Crystal Structures of Fludarabine-TP and Vidarabine-TP Bound to Pri1. Primase initiates RNA primer synthesis using two distinct nucleotide binding pockets: (i) the initiation site, which utilizes several key residues on Pri2-CTD to bind the first nucleotide that forms the 5'-end of the RNA primer, and (ii) the Pri1 elongation site that binds all subsequent nucleotides and adds them to the 3'-end of the growing primer. 30 Following synthesis of the first dinucleotide, which involves both Pri1 and Pri2, further nucleotide addition requires only the elongation site on Pri1. 33,44 To obtain atomic details of the interaction between ara nucleotides and the elongation site of human Pri1, we soaked vidarabine-TP and fludarabine-TP into Pri1 crystals that diffracted to high resolution and in which the active site was free from lattice contacts. For comparison, we determined in the same way the crystal structures of Pri1 bound to ATP, 2F-ATP, and dATP. Given the higher affinity of Pri1 for ATP in the presence of Mn\( ^{2+} \) \( \left( K_{d}^{\text{ATP}} = 0.41 \mu\text{M}, \text{Supplementary Figure 1C} \right) \), we supplemented the nucleotide-containing crystal soak solutions with 500 \( \mu\text{M} \) Mn\( ^{2+} \). Data collection and refinement statistics are given in Table 1. For each nucleotide soak, a Fo-Fc omit map clearly revealed a single nucleotide bound to the elongation pocket of Pri1 (Supplementary Figure 2A–E). Final 2Fo-Fc electron density maps for each of the nucleotides are shown in Figure 4A.

This high resolution structural information allowed us to compare in detail the interactions of the different sugar moieties with the Pri1 active site. As described previously, human Pri1 adopts the mixed \( \alpha/\beta \) primase (Prim) fold

---

**Figure 2.** Effect of fludarabine-TP on RNA primer synthesis. a) Denaturing gel showing the dose-dependent inhibition of RNA primer synthesis by fludarabine-TP (fu-TP). Reactions contained 0.5 \( \mu\text{M} \) polyT40 ssDNA template, 0.5 \( \mu\text{M} \) primase, 500 \( \mu\text{M} \) ATP, 10 mM Mg(OAc)\(_2\), and the indicated concentration of fu-TP. Reactions were incubated at 37 \(^\circ\text{C}\) for 30 min. b) Denaturing gel showing the incorporation of fludarabine into an existing RNA primer. The template comprised a 38-mer DNA template (\( 5'\)-T\( _{m}^{\text{CGCCCAAACG}} \)) annealed to an 18-mer RNA primer (\( 5'\)-UUGGGCGCUCUCUGG). Reactions contained 0.5 \( \mu\text{M} \) annealed DNA-RNA template, 0.5 \( \mu\text{M} \) primase, 10 mM Mg(OAc)\(_2\), and 500 \( \mu\text{M} \) ATP or fu-TP. Reactions were incubated at 37 \(^\circ\text{C}\) for the indicated time. c) Denaturing gel showing that primase is unable to extend an RNA primer following fludarabine incorporation. 0.5 \( \mu\text{M} \) primase was incubated with 0.5 \( \mu\text{M} \) DNA(38)-RNA(18) template and either 500 \( \mu\text{M} \) ATP (lane 3) or 500 \( \mu\text{M} \) fu-TP (lane 4) for 30 min at 37 \(^\circ\text{C}\). ATP (0.5 or 10 mM) was subsequently added to the fu-TP sample and incubated for a further 30 min (lanes 5, 6). All gels were poststained with Sybr Gold. M = marker.

**Figure 3.** ara nucleotides show enhanced binding to and stabilization of human primase. a) FP-based competition binding experiment in which 6FAM-ATP (30 nM) in the presence of excess Pri1 (1.5 \( \mu\text{M} \)) was challenged with increasing concentrations of the indicated nucleotide. Each data point represents the mean ± SD (n = 3). b) First derivative of the thermal denaturation curve for the chimeric Pri1-Pri2\( ^{\text{ACTP}}\)-Pol \( \alpha \) construct (see Methods) in the presence of the indicated nucleotide or nucleotide analogue. Single, representative curves are shown. Calculated melting temperatures: \( T_{m}^{\text{apo}} \left( 50.5 \pm 0.2 ^\circ\text{C} \right), \; T_{m}^{\text{ATP}} \left( 53.8 \pm 0.3 ^\circ\text{C} \right), \; T_{m}^{\text{dATP}} \left( 54.5 \pm 0.1 ^\circ\text{C} \right), \; T_{m}^{\text{2F-ATP}} \left( 54.3 \pm 0.1 ^\circ\text{C} \right), \; T_{m}^{\text{vid-TP}} \left( 54.4 \pm 0.2 ^\circ\text{C} \right), \; T_{m}^{\text{fu-TP}} \left( 58.0 \pm 0.2 ^\circ\text{C} \right) \) (mean ± SD, n = 4). RFU: relative fluorescence units.
interaction is important for catalysis because cordycepin-TP RNA primer synthesis when present in excess of ATP isized onto an existing RNA primer and only starts to inhibit aliphatic side chain of Leu317. In the ATP- and 2F-ATP-bound structures, the 2′-OH of the ribose inserts between the main-chain carbonyl group of Leu316 and the carboxylate group of the Asp79 side chain and is positioned roughly equidistant between these two moieties. However, in the vidarabine-TP and fludarabine-TP bound structures, the 2′-OH points directly toward the carboxylate group of Asp79 and the ε-amino group of Lys77 and away from the carbonyl O of Leu316 (Figure 4C). In this way, the ara nucleotides present the 2′-OH in an orientation that is more favorable for hydrogen bond formation compared to the normal ribonucleotides. The fluorine atom on the base moiety of fludarabine-TP resides above the side chain of Leu316 (Figure 4C) and only 3.6–3.9 Å away from the side chain of the catalytically essential residue Arg56. This conserved and catalytically crucial pocket could certainly be explored further in future structure-based drug design efforts.

The vidarabine-TP and fludarabine-TP crystal structures indicate that the side chain of residues Lys77 and/or Asp79 may be responsible for the observed preference of primase for ara nucleotides. We attempted to confirm this using Pri1 mutagenesis. While the K77A mutant behaved as wild-type, the D79A point mutant did show a slight weakening of the interaction between Pri1 and ara nucleotide (data not shown). However, we suspect the analysis may be complicated by partial redundancy between the two side chains and/or a more complex binding mode which will require further investigation.

### Table 1. Data Collection and Refinement Statistics for the Crystal Structures of Pri1 Bound to Nucleotides and Nucleotide Analagues

|                  | ATP      | dATP     | 2F-ATP   | Vid-TP   | Flu-TP    |
|------------------|----------|----------|----------|----------|----------|
| accession code   | 6R4S     | 6R5D     | 6RSE     | 6R4T     | 6R4U     |
| data collection  |          |          |          |          |          |
| wavelength (Å)   | 0.979    | 0.917    | 1.039    | 0.979    | 0.979    |
| space group      | C2221    | C2221    | C2221    | C2221    | C2221    |
| cell dimensions  |          |          |          |          |          |
| a, b, c (Å)      | 110.1, 117.3, 151.2 | 110.5, 117.3, 151.7 | 110.5, 117.2, 152.1 | 111.1, 119.0, 150.7 | 110.8, 117.6, 148.8 |
| α, β, γ (°)      | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 |
| molecules/asymmetric unit | 2 | 2 | 2 | 2 | 2 |
| resolution (Å)   | 29.32–2.75 (2.91–2.73) | 46.40–1.95 (2.07–1.95) | 46.41–1.85 (1.96–1.83) | 46.69–2.35 (2.49–2.35) | 46.13–2.20 (2.33–2.20) |
| unique reflections | 25616 (2462) | 71418 (11299) | 82430 (12971) | 41814 (6609) | 49380 (7541) |
| R_{free}         | 0.18 (0.92) | 0.09 (1.20) | 0.08 (0.77) | 0.08 (1.05) | 0.10 (1.38) |
| mean l/nl        | 5.46 (1.04) | 14.56 (1.33) | 11.52 (1.52) | 15.35 (1.63) | 12.91 (1.52) |
| completeness, %  | 96.8 (94.5) | 99.2 (98.0) | 97.7 (95.8) | 99.7 (98.7) | 99.2 (95.3) |
| redundancy        | 4.95     | 6.75     | 4.39     | 7.20     | 6.50     |
| CC1/2, %         | 0.98 (0.36) | 1.00 (0.75) | 1.00 (0.77) | 1.00 (0.81) | 1.00 (0.83) |
| Wilson B-factor  | 67.09    | 37.03    | 34.23    | 62.01    | 44.70    |

### Refinement

| non-hydrogen atoms | 6541 | 7033 | 7007 | 6638 | 6734 |
|-------------------|------|------|------|------|------|
| R_{work}/R_{free} | 22.8/26.9 | 17.8/21.5 | 17.8/20.6 | 20.9/23.9 | 19.6/22.3 |
| average B factor  | 71.36 | 49.46 | 45.47 | 81.21 | 57.34 |
| clashscore        | 2.79 | 1.36 | 1.51 | 1.46 | 1.31 |
| rotamer outliers, % | 0.56 | 0.27 | 0.41 | 0.00 | 0.83 |
| rmsd bond lengths | 0.004 | 0.003 | 0.003 | 0.004 | 0.003 |
| bond angles       | 0.63 | 0.63 | 0.66 | 0.68 | 0.53 |
| Ramachandran analysis |      |      |      |      |      |
| preferred region, % | 96.83 | 96.71 | 97.09 | 96.98 | 97.22 |
| allowed regions, % | 3.17 | 3.15 | 2.91 | 3.02 | 2.78 |
| outliers, %       | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 |

*Statistics in parentheses indicate those for the highest resolution shell.*
The ara 2′-OH Is Crucial for Mediating Effective Primase Inhibition. To investigate whether primase inhibition is a shared property of chemotherapeutic nucleotide analogues, we examined RNA primer synthesis activity in the presence of an extended repertoire of these agents, including gemcitabine-TP, cytarabine-TP, and clofarabine-TP (Figure 1A). On a ssDNA template, titration of cytarabine-TP resulted in very similar levels of primer inhibition to fludarabine-TP (Figure 5A). Given that cytarabine-TP and fludarabine-TP are CTP and ATP analogues, respectively, this experiment was conducted using a ssDNA template containing equal quantities of T and G. This result was corroborated in a fluorescence-based primer synthesis assay, which showed similar levels of inhibition for fludarabine-TP, vidarabine-TP, and cytarabine-TP (Figure 5B). In addition, cytarabine was readily incorporated into an existing RNA primer, as described previously (Supplementary Figure 4B). These results further confirm that primase inhibition by ara 2′-OH nucleotide analogues is largely unaffected by the nature of the base moiety.

By contrast, gemcitabine-TP and clofarabine-TP, which both contain an ara 2′-F rather than ara 2′-OH, did not inhibit RNA primer synthesis over the range of concentrations tested (Figure 5C). In addition, in an FP-based competition binding experiment, gemcitabine-TP and clofarabine-TP produced very similar $K_{1/2}$ values to ATP (Supplementary Figure 4A). This is consistent with the structural data presented here, as an ara 2′-F would be unable to form a favorable hydrogen bond with the carboxylate side chain of Asp79. Interestingly, in the presence of nucleotide analogue alone, while clofarabine was poorly incorporated into an existing RNA primer, gemcitabine was readily incorporated (Supplementary Figure 4B). We conclude that, while primase can incorporate gemcitabine into RNA primers, this analogue does not exert significant inhibition of primer synthesis in the presence of the natural ribonucleotides. This is probably due to its weaker binding affinity compared to the ara 2′-OH nucleotide analogues. Taken together, these results indicate that a hydrogen bond donor in the 2′ position of the arabinose sugar moiety is crucial for mediating effective primase inhibition by these nucleotide analogues.

In conclusion, we have analyzed in detail the mode of binding of anticancer agent fludarabine-TP and antiviral agent vidarabine-TP to human Pri1. Thermal denaturation, competition, and primer synthesis experiments all confirm that these arabinofuranosyl nucleotides are bona fide inhibitors of primase, as is the CTP-analogue, cytarabine-TP. Given that these ara nucleotides inhibit primase to a significant degree in the presence of excess normal ribonucleotides in vitro (Figure 2A, Figure 5A) and the fact that fludarabine-TP can accumulate to concentrations in the range of hundreds of micromolar inside cells, it is possible that primase may indeed be one of the relevant targets of this chemotherapeutic agent in vivo. Whether primase inhibition by fludarabine-TP or cytarabine-TP is one of the primary modes of cytotoxicity toward cancer cells remains to be determined and will be the subject of future experiments.

Gemcitabine, cytarabine, fludarabine, and clofarabine are all used as cytotoxic anticancer agents in the clinic, but despite structural similarities, their mode of action and in vivo stability seems to vary quite significantly. Recently, human PrimPol (a second human primase, involved in translesion synthesis) was shown to incorporate cytarabine-TP and gemcitabine-TP, but not two antiviral nucleoside analogues (emtricitabine and lamivudine), into newly synthesized DNA strands. These
studies highlight how important it will be to analyze the effect of each nucleotide analogue on a range of intracellular targets in order to begin to understand their nuanced activity in vivo.

The data presented here indicate that chemotherapeutic nucleotides cytarabine-TP and fludarabine-TP, but not gemicitabine-TP or clofarabine-TP, are likely to be effective inhibitors of primase activity in vivo. They bind more tightly to intracellular enzymes, thereby modulating their activity, more selective inhibitor of human primase (Pri1-Pri2). This may result in a new chemotherapeutic agent that generates a higher affinity, more selective inhibitor of human primase. Further advances were hindered by a lack of structural information relating to the mode of binding of this agent to the primase active site. Based on the structural data presented here, we hypothesize that it should be possible to further optimize the binding of ara nucleotides to Pri1, in order to generate a higher affinity, more selective inhibitor of human primase. This may result in a new chemotherapeutic agent so that they target specific combinations of intracellular enzymes, thereby modulating their effect in vivo.

## EXPERIMENTAL METHODS

### Nucleotides and Nucleotide Analogues

2′-F-adenosine triphosphate (2′-F-ATP) (NU-1455), vidarabine-TP (NU-1115), fludarabine-TP (NU-10703-10), gemicitabine-TP (NU-16075), clofarabine-TP (NU-874), cytarabine-TP (NU-1607), gemcitabine-TP (NU-11705), and N9-(6-aminohexyl)-ATP-6FAM (NU-805-6FM) were purchased from Jena Bioscience.

### Cloning, Expression, and Protein Purification

Heterodimeric human primase (Pri1-Pri2) was coexpressed in bacteria as full-length His6-tagged Pri1 (amino acids 1 to 420) and Pri2 (1 to 462). Residues 463 to 509 of Pri2 were omitted to minimize proteolytic degradation. These residues are not conserved and are disordered in the crystal structure of full-length human primase. Primer synthesis assays confirmed that this protein showed identical activity to the wild-type protein (Supplementary Figure S). Human Pri1 was produced as either full-length His6-tagged Pri1 (1 to 420, WT or D109A point mutant) for fluorescence polarization experiments or His6-tagged Pri1 (1 to 407) for crystallization. Due to exposed hydrophobic patches on both Pri1 and Pri2 that interfered with the analysis, thermal melt experiments were performed using a chimeric construct of human primase (Pri1-Pri2) comprising Pol α residues 1445 to 1462 (GYSEVNLKLFCAVKS) fused via a 15 residue Gly-Ser-Thr linker to residue N19 of Pri2. In this protein, the tethered Pol α peptide binds to a hydrophobic patch on the N-terminal domain of Pri1, while the Pri1 elongation site is unaffected.

All proteins were expressed in the Rosetta2 (DE3) E. coli strain from the pRSDuet-1 vector (Novagen). The purification protocol entailed Ni-NTA agarose chromatography (Qiagen), heparin sepharose chromatography (GE Healthcare), His-tag cleavage by TEV protease, and size exclusion chromatography. The size exclusion buffer comprised either 25 mM HEPES pH 7.2, 300 mM KCl, 5% (v/v) glycerol, and 1 mM TCEP (for Pri1-Pri2) or 25 mM HEPES pH 7.2, 150 mM KCl, 5% (v/v) glycerol, and 1 mM TCEP (for Pri1). Purified proteins were concentrated, and aliquots were flash frozen in liquid nitrogen and then stored at −80 °C. Final yields of protein were 2 mg per liter of culture for Pri1 and 5 mg per liter of culture for Pri1-Pri2.

### Crystallization and X-ray Crystallography

Apo Pri1 (1 to 407) was crystallized by vapor diffusion at 19 °C, by mixing 1 μL of 150 μM Pri1 with 1 μL of crystallization buffer: 0.1 M Bis Tris propane pH 6.5, 24% (v/v) PEG 3350, 0.15 M NaF. Diffraction data were collected at SOLEIL synchrotron (beamline PROXIMA 1). The protein crystallized in space group P43212, with one copy of Pri1 in the asymmetric unit. Diffraction data were indexed, integrated, and scaled using XDS, and the structure was solved by molecular chain termination of nascent RNA primers (Figure 2C). Thus, it is likely that their inhibitory action is a result of both competitive inhibition and capping of the RNA primer resulting in chain termination.

It should now be possible to build on previous work outlining the synthesis of novel ara nucleotide analogue compounds as potent primase inhibitors. Initial work was promising, describing a nucleotide analogue (araBTP) with improved selectivity for primase over DNA polymerase α, but further advances were hindered by a lack of structural information relating to the mode of binding of this agent to the primase active site. Based on the structural data presented here, we hypothesize that it should be possible to further optimize the binding of ara nucleotides to Pri1, in order to generate a higher affinity, more selective inhibitor of human primase. This may result in a new chemotherapeutic nucleotide analogues so that they target specific combinations of intracellular enzymes, thereby modulating their effect in vivo.
replacement in Phaser\textsuperscript{60} using 4BU as the search model.\textsuperscript{61} The model was completed by alternating between cycles of manual rebuilding in Coot\textsuperscript{31} and structure refinement in PhenixRefine.\textsuperscript{62} Unfortunately, while these crystals diffracted to high resolution (1.5 Å), they were often multiple and/or poorly reproducible, and the crystallization condition was therefore optimized for the nucleotide soaking experiments. Pri1 was subsequently crystallized by vapor diffusion at 19 °C, by mixing 1.5 μL of 150 μM Pri1 with 1 μL of crystallization buffer: 23% (v/v) PEG 3350, 10% (v/v) ethylene glycol, 200 mM Na2/K tartrate. Crystals were soaked overnight in crystallization buffer containing 500 μM nucleotide (ATP, dATP, 2F-ATP, vidarabine-TP, or fludarabine-TP) and 500 μM MnCl2. Diffraction data were collected at beamlines I24 (ATP, 2F-ATP, and vidarabine-TP), 102-(dATP), and 102 (fludarabine-TP) of the Diamond Light Source, UK. The protein crystalized in space group C222\(_1\), with two copies of Pri1 in the asymmetric unit (Table 1). The apo Pri1 structure described above was used as the molecular replacement model. Ligand restraints were generated using grade (Global Phasing Ltd.). Data were processed, and the model was refined as described above. Owing to poor electron density, the following residues were considered disordered and omitted from the final model: apo Pri1 (chain A: 360–381); Pri1.ATP (chain A: 1–2, 360–381, 407; chain E: 1, 360–381, 407), Pri1.dATP (chain A: 1–4, 361–379; chain E: 1, 361–381), Pri1.2F-ATP (chain A: 1–5, 361–379; chain E: 1–3, 361–381, 407), Pri1.vidarabine-TP (chain A: 1–5, 362–379; chain D: 1, 361–381), Pri1.fludarabine-TP (chain A: 1–5, 361–380; chain E: 1–3, 360–381).

**Fluorescence-Based Primase Activity Assays.** Time-course RNA primer synthesis assays were performed in triplicate in 96 well plate format. Each well contained 1 μM Pri1-Pri2 and 200 nM ssDNA (5'-GGTGTGTCATTTAGCTACCTCGTGTGCCT) in 25 mM HEPES pH 7.0, 120 mM NaCl, 1 mM TCEP, 5 mM MgCl2 (or 1 mM MnCl2). Reactions were initiated by the addition of 20 μM of each ribonucleotide (ATP, CTP, GTP, and UTP) and 20 μM nucleotide analogue (ATP, dATP, 2F-ATP, vidarabine-TP, or fludarabine-TP), to give a final reaction volume of 25 μL. The plate was incubated at 37 °C in the presence of MnCl2 or 25°C in the presence of MgCl2. Reactions were quenched at the indicated time points by the addition of 25 μL of a 1:100 dilution of Picogreen (Thermo Fisher Scientific) in 25 mM Tris pH 8.0 and 20 mM EDTA. Following incubation of the plate at 37 °C for 10 min, fluorescence intensity measurements were recorded in a PHERAstar Plus multidetection plate reader (BMG Labtech) equipped with fluorescence intensity of a well containing protein, nucleotide, and 30-mer dsDNA labeled ATP and 1.5 μM Pri1, and nucleotide analogue was titrated in increasing concentrations, from 0 to 200 μM. Binding buffer comprised 25 mM HEPES pH 7.0, 120 mM NaCl, 1 mM TCEP, and 1 mM MnCl2. Fluorescence anisotropy measurements were recorded in a PHERAstar Plus multidetection plate reader (BMG Labtech), as described above. Monte Carlo curve fitting was performed in ProFit (QuantumSoft). K\(_i\)/2 values are reported, representing the concentration of ligand required to reduce the signal to half its original value.

**Thermal Denaturation.** Reactions were performed in quadruplicate, in 96 well plate format. Each well contained 6.3 μM Pri1-Pri2\textsuperscript{2221}, Pol α chimera, 500 μM MnCl2, 500 μM nucleotide, and 5× SYPRO orange dye (Sigma-Aldrich), in a reaction buffer comprising 25 mM HEPES pH 7.0, 150 mM NaCl, and 1 mM TCEP. Heating was performed in a CFX Connect Real-time PCR detection system with a 90-well reaction module (Bio-Rad), using a ramp rate of 0.2 °C/min. The negative of the first derivative of the fluorescence signal was plotted against temperature, and the melting temperature (T\(_m\)) was estimated from the local minimum of the curve peak.

**Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acschembio.9b00367.

Figure 1, effect of divalent metals on primase activity and nucleotide binding; Figure 2, Fo-Fc omit maps; Figure 3, effect of cordycepin-TP on primase activity; Figure 4, effect of cytarabine-TP, clofarabine-TP, and gemicitabine-TP on primase activity; and Figure 5, C-terminal truncation of Pri2 has no effect on primase activity (PDF).

**Accession Codes**

The coordinates and structure factors for the crystal structures presented in this paper have been deposited in the PDB under accession codes 6R4S (Pri1.ATP), 6RSD (Pri1.dATP), 6RSE (Pri1.2F-ATP), 6R4T (Pri1.vidarabine-TP), 6R4U (Pri1.fludarabine-TP), and 6R84 (apo Pri1).

**Author Information**

*Corresponding Author*

Phone: +44 1223 333652. E-mail: mlk26@cam.ac.uk.

**ORCID**

Luca Pellegrini: 0000-0002-9300-497X

Mairi L. Kilkenny: 0000-0002-7280-8522

**Author Contributions**

M.L.K. designed the experiments and analyzed results. M.L.K. and S.H. performed the competition binding experiments and fluorescence-based primer synthesis assays. M.L.K. and L.R.S. performed the cytarabine-TP, gemicitabine-TP, and clofarabine-TP primer synthesis assays. M.J.B. optimized the gel-based primer synthesis assay and carried out the initial fludarabine-TP and vidarabine-TP studies. M.L.K. and N.J.R. collected the X-ray diffraction data. L.P. and M.L.K. conceived the project and directed the research. M.L.K. wrote the manuscript, with contributions from all authors.
ACKNOWLEDGMENTS

We thank Diamond Light Source for access to beamlines I02, I04-1, and I24 (MX5S37) that contributed to the results presented here. We also acknowledge SOLEIL for the provision of synchrotron radiation facilities and would like to thank the staff of beamline PROXIMA1 for assistance. We are grateful to the Facility Managers of the Crystallographic X-ray Facility (D. Chirgadze) and the Biophysics Facility (K. Stott) at the Department of Biochemistry, University of Cambridge for their assistance in using these facilities. We are grateful to J. Maman for expert advice on all fluorescence measurements. This work was funded by a Wellcome Trust Investigator Award (104641/Z/14/Z) to L.P. S.H. was funded by a Boehringer-Ingelheim Fonds PhD Fellowship, Janggen-Pöhn-Stiftung Award, and Swiss National Science Foundation Award.

REFERENCES

(1) Pellegrini, L., and Costa, A. (2016) New Insights into the Mechanism of DNA Duplication by the Eukaryotic Replisome. Trends Biochem. Sci. 41, 859–871.
(2) Frick, D. N., and Richardson, C. C. (2001) DNA Primases. Annu. Rev. Biochem. 70, 39–80.
(3) Lucchini, G., Francesconi, S., Foiani, M., Badaracco, G., and Plevani, P. (1987) Yeast DNA polymerase–DNA primase complex; cloning of PRI I, a single essential gene related to DNA primase activity. EMBO J. 6, 737–742.
(4) Cloutier, S., Hamel, H., Champagne, M., and Yotov, W. V. (1999) Mapping of the human DNA primase 1 (PRIM1) to chromosome 12q13. Genomics 43, 398–401.
(5) Yotov, W. V., Hamel, H., Rivard, G.-E., Champagne, M. A., Russo, P. A., Leclerc, J.-M., Bernstein, M. L., and Levy, E. (1999) Amplifications of DNA Primase 1 (PRIM1) in Human Osteosarcoma. Genes, Chromosomes Cancer 26, 62–69.
(6) Lee, W., Chen, L., Lee, C., Huang, C., Ho, Y., Yang, P., Ho, C., Chang, H., Lin, I., Chang, H., Liu, Y., Wu, C., and Tu, S. (2019) DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint. Int. J. Cancer 144, 615–630.
(7) Teleopsis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopan, E., Dovey, O. M., Mupo, A., Grinkevich, L., M., Mazan, M., Godzeka, M., Ohnishi, S., Cooper, J., Patel, M., McKeirrell, T., Chen, B., Domingues, A. F., Gallipoli, P., Teichmann, S., Ponstingl, H., McDermott, U., Saez-Rodriguez, J., Huntly, B. J. P., Iorio, F., Pina, C., Vassiliou, G. S., and Yusa, K. (2016) A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Rep. 17, 1193–1205.
(8) Hocke, S., Guo, Y., Job, A., Orth, M., Ziehs, A., Lauber, K., De Toni, E. N., Gress, T. M., Herbst, A., Göke, B., and Gallmeier, E. (2016) A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLQ1-deficient cancers. Oncotarget 7, 7080–7095.
(9) Job, A., Schmitt, L. M., von Wenserski, L., Lankat-Buttgereit, B., Gress, T. M., Buchholz, M., and Gallmeier, E. (2018) Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors. Neoplasia 20, 1135–1143.
(10) Plunkett, W., and Saunders, P. P. (1991) Metabolism and action of purine nucleoside analogs. Pharmacol. Ther. 49, 239–268.
(11) Jordheim, L. P., Durante, D., Zoulim, F., and Dumontet, C. (2015) Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discovery 12, 447–464.
(12) Huang, P., Sandoval, A., Van Den Neste, E., Keating, M. J., and Plunkett, W. (2000) Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 14, 1405–1413.
(13) De Clercq, E., and Li, G. (2016) Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695–747.
(14) Chun, H. G., Leyland-Jones, B., and Cheson, B. D. (1991) Fludarabine Phosphate: A Synthetic Purine Antimetabolite With Significant Activity Against Lymphoid Malignancies. J. Clin. Oncol. 9, 175–188.
(15) Tamamyan, G., Kadia, T., Ravandi, F., Borthakur, G., Cortes, J., Jabbour, E., Daver, N., Oertle, M., Kantarjian, H., and Konopleva, M. (2017) Frontline treatment of acute myeloid leukemia in adults. Crit. Rev. Oncol. Hematol. 110, 20–34.
(16) Lukenbill, J., and Kalaycio, M. (2013) Fludarabine: A review of the clear benefits and potential harms. Leuk. Res. 37, 986–994.
(17) Fidias, P., Chabner, B. A., and Grossbard, M. L. (1996) Purine analogs for the treatment of low-grade lymphoproliferative disorders. Oncologist 1, 125–139.
(18) Parker, W. B., Bapat, A. R., Shen, J., Townsend, A. J., and Cheng, Y. (1988) Interaction of 2-Halogenated dATP Analogs (F, Cl, and Br) with Human DNA Polymerases, DNA Primase and Ribonucleotide Reductase. Mol. Pharmacol. 34, 485–491.
(19) Tseng, W. C., Derse, D., Cheng, Y. C., Brockman, R. W., and Bennett, L. L. (1982) In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol. 21, 474–477.
(20) White, E. L., Shaddix, S. C., Brockman, R. W., and Bennett, L. L. (1982) Comparison of the Actions of 9-beta-D-Arabinofuranosyl-2-fluoroadenine and 9-beta-D-Arabinofuranosyladenine on Target Enzymes from Mouse Tumor Cells. Cancer Res. 42, 2260–2264.
(21) Yang, S., Huang, P., Plunkett, W., Becker, F. C., and Chan, J. Y. H. (1992) Dual Mode of Inhibition of Purified DNA Ligase I from Human Cells by 9-beta-D-Arabinofuranosyl-2-fluoroadenine Triphosphate. J. Biol. Chem. 267, 2345–2349.
(22) Huang, P., Chubb, S., and Plunkett, W. (1990) Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J. Biol. Chem. 265, 16617–16625.
(23) Wistittpithaya, S., Zhao, Y., Long, J. M., Ci, M., Fletcher, E. A., Blessing, W. A., Weiss, R. S., and Aye, Y. (2016) Cladrabine and Fludarabine Nucleotides Induce Distinct Hexamers Defining a Common Mode of Reversible RNR Inhibition. ACS Chem. Biol. 11, 2021–2032.
(24) Huang, P., and Plunkett, W. (1991) Action of 9-beta-D-Arabinofuranosyl-2-fluoroadenine on RNA Metabolism. Mol. Pharmacol. 39, 449–455.
(25) Plunkett, W., Chubb, S., Alexander, L., and Montgomery, J. A. (1980) Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res. 40, 2349–2355.
(26) Dicioccio, R. A., and Svrastova, B. I. S. (1977) Kinetics of Inhibition of Deoxyribonucleotide-Polymerizing Enzyme Activities from Normal and Leukemic Human Cells by 9-beta-D-Arabinofuranosyladenine 5′-Triphosphate and 1-beta-D-Arabinofuranosylcytosine 5′-Triphosphate. Eur. J. Biochem. 79, 411–418.
(27) Yoshida, S., Suzuki, R., Masaki, S., and Koivai, O. (1985) Arabinosyladenine 5′-triphosphate inhibits DNA primase of calf thymus. J. Biochem. 98, 427–433.
(28) Parker, W. B., and Cheng, Y. (1986) Inhibition of DNA Primase by Nucleoside Triphosphates and Their Arabinofuranosyl Analogs. Mol. Pharmacol. 31, 146–151.
(29) Catapano, C. V., Perrino, F. W., and Fernandes, D. J. (1993) Primer RNA Chain Termination Induced by 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5′-Triphosphate. J. Biol. Chem. 268, 7179–7185.
(30) Harrington, C., and Perrino, F. W. (1995) The Effects of Cytosine Arabinoside on RNA-primed DNA Synthesis by DNA Polymerase α-Primase. J. Biol. Chem. 270, 26664–26669.
(31) Kuchta, R. D., Ilsey, D., Kravig, K. D., Schubert, S., and Harris, B. (1992) Inhibition of DNA Primase and Polymerase α by...
arabinofuranosyl nucleoside triphosphates and related compounds. Biochemistry 31, 4720–4722.

(32) Kuchta, R. D., and Willhelm, L. (1991) Inhibition of DNA Primase by 9-beta-D-Arabinofuranosyladenosine triphosphate. Biochemistry 30, 797–803.

(33) Catapano, C. V., Chandler, K. B., and Fernandes, D. J. (1991) Inhibition of Primer RNA Formation in CCRF-CEM Leukemia Cells by Fludarabine Triphosphate. Cancer Res. 51, 1829–1835.

(34) Moore, C. L., Chiairamonte, M., Higgins, T., and Kuchta, R. D. (2002) Synthesis of Nucleotide Analogues That Potently and Selectively Inhibit Human DNA Primase. Biochemistry 41, 14066–14075.

(35) Kilkenney, M. L., Longo, M. A., Perera, R. L., and Pellegrini, L. (2013) Structures of human primase reveal design of nucleotide elongation site and mode of Pol α tethering. Proc. Natl. Acad. Sci. U. S. A. 110, 15961–15966.

(36) Vaihuligalam, S., Arnett, D. R., Aggarwal, A., Eichman, B. F., Fanning, E., and Chazin, W. J. (2014) Insights into eukaryotic primer synthesis from structures of the p58 subunit of human DNA primase. J. Mol. Biol. 426, 558–569.

(37) Koeppl, S. A., Hanson, S., Hinrichs, S. H., and Griep, M. A. (2005) Fluorometric assay for bacterial primases. Anal. Biochem. 339, 353–355.

(38) Kirk, B. W., and Kuchta, R. D. (1999) Human DNA primase: anion inhibition, manganese stimulation, and their effects on in vitro start-site selection. Biochemistry 38, 10126–10134.

(39) Copeland, W. C., Lam, N. K., and Wang, T. S. F. (1993) Fidelity studies of the human DNA polymerase α. J. Biol. Chem. 268, 11041–11049.

(40) Richardson, K. A., Vega, T. P., Richardson, F. C., Moore, C. L., Robloff, J. C., Tomkinson, B., Bendele, R. A., and Kuchta, R. D. (2004) Polymerization of the triphosphates of AraC, 2′,2′-difluorodeoxycytidine (dFdC) and OSI-7836 (T-arAC) by human DNA polymerase α and DNA primase. Biochem. Pharmacol. 68, 2337–2346.

(41) Baranovskiy, A. G., Babayeva, N. D., Zhang, Y., Gu, J., Suwa, Y., Pavlov, Y. I., and Tahirov, T. H. (2016) Mechanism of Concerted RNA-DNA Primer Synthesis by the Human Primosome. J. Biol. Chem. 291, 10006–10020.

(42) Copeland, W. C., and Wang, T. S. F. (1993) Enzymatic characterization of the individual mammalian primase subunits reveals a biphasic mechanism for initiation of DNA replication. J. Biol. Chem. 268, 26179–26189.

(43) Klinge, S., Hirst, J., Maman, J. D., Krude, T., and Pellegrini, L. (2007) An iron-sulfur domain of the eukaryotic primase is essential for RNA primer synthesis. Nat. Struct. Mol. Biol. 14, 875–877.

(44) Zerbe, L. K., and Kuchta, R. D. (2002) The p58 subunit of human DNA primase is important for primer initiation, elongation, and counting. Biochemistry 41, 4891–4900.

(45) Copeland, W. C., and Tan, X. (1995) Active site mapping of the catalytic mouse primase subunit by alanine scanning mutagenesis. J. Biol. Chem. 270, 3905–3913.

(46) Gandhi, V., and Plunkett, W. (2002) Cellular and clinical pharmacology of fludarabine. Clin. Pharmacokinet. 41, 93–103.

(47) Srikanth, V., Batista, V. S., Ji, X., Reiss, K., Tofeleanu, F., Cinatl, J., Buzovetsky, O., Ferreiros, N., Kaderali, L., Xiong, Y., Keppler, O. T., Schneider, C., Thomas, D., Geisslinger, G., and Knecht, K. M. (2018) The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1. Proc. Natl. Acad. Sci. U. S. A. 115, E10022–E10031.

(48) Tokarsky, E. J., Wallenmeyer, P. C., Phi, K. K., and Suo, Z. (2017) Significant impact of divalent metal ions on the fidelity, sugar selectivity, and drug incorporation efficiency of human PrimPol. DNA Repair 49, 51–59.

(49) Kabsch, W. (2010) XDS. Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 125–132.

(50) McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674.

(51) Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 486–501.